Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.

Foster LH, Lum LG.

Expert Opin Biol Ther. 2019 Jul;19(7):707-720. doi: 10.1080/14712598.2019.1604672. Epub 2019 May 13.

PMID:
31081696
2.

Immune T cells can transfer and boost anti-breast cancer immunity.

Thakur A, Rathore R, Kondadasula SV, Uberti JP, Ratanatharathorn V, Lum LG.

Oncoimmunology. 2018 Aug 27;7(12):e1500672. doi: 10.1080/2162402X.2018.1500672. eCollection 2018.

3.

Bispecific antibody based therapeutics: Strengths and challenges.

Thakur A, Huang M, Lum LG.

Blood Rev. 2018 Jul;32(4):339-347. doi: 10.1016/j.blre.2018.02.004. Epub 2018 Feb 20. Review.

PMID:
29482895
4.

Bispecific Antibody Armed T Cells to Target Cancer Cells.

Thakur A, Lum LG, Mittal S.

Methods Mol Biol. 2018;1722:117-126. doi: 10.1007/978-1-4939-7553-2_8.

PMID:
29264802
5.

Immune Modulation Therapy and Imaging: Workshop Report.

Shields AF, Jacobs PM, Sznol M, Graham MM, Germain RN, Lum LG, Jaffee EM, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung DK, Wu AM, Sharon E, Shankar LK.

J Nucl Med. 2018 Mar;59(3):410-417. doi: 10.2967/jnumed.117.195610. Epub 2017 Aug 17.

6.

Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.

Al-Kadhimi Z, Gul Z, Abidi M, Lum LG, Deol A, Chen W, Jang H, Ozust C, Langston A, Waller E, Uberti J.

Bone Marrow Transplant. 2017 Sep;52(9):1304-1310. doi: 10.1038/bmt.2017.95. Epub 2017 Jun 5.

PMID:
28581472
7.

Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.

Modi D, Jang H, Kim S, Surapaneni M, Sankar K, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Chandrasekar P, Uberti JP.

Support Care Cancer. 2017 Aug;25(8):2593-2601. doi: 10.1007/s00520-017-3670-3. Epub 2017 Apr 2.

PMID:
28365897
8.

Cancer Immunology and Immunotherapy.

Sukari A, Nagasaka M, Al-Hadidi A, Lum LG.

Anticancer Res. 2016 Nov;36(11):5593-5606. Review.

PMID:
27793882
9.

Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation.

Modi D, Jang H, Kim S, Deol A, Ayash L, Bhutani D, Lum LG, Ratanatharathorn V, Manasa R, Mellert K, Uberti JP.

Am J Hematol. 2016 Sep;91(9):E341-7. doi: 10.1002/ajh.24435. Epub 2016 Jul 14.

10.

In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer.

Thakur A, Lum LG.

Oncoimmunology. 2015 Jul 15;5(3):e1055061. eCollection 2016 Mar.

11.

Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma.

Xie Y, Kim NH, Nadithe V, Schalk D, Thakur A, Kılıç A, Lum LG, Bassett DJP, Merkel OM.

J Control Release. 2016 May 10;229:120-129. doi: 10.1016/j.jconrel.2016.03.029. Epub 2016 Mar 19.

12.

"NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.

Thakur A, Lum LG.

Expert Opin Biol Ther. 2016;16(5):675-88. doi: 10.1517/14712598.2016.1150996. Epub 2016 Mar 16. Review.

PMID:
26848610
13.

Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.

Lum LG, Thakur A, Kondadasula SV, Al-Kadhimi Z, Deol A, Tomaszewski EN, Yano H, Schalk DL, Ayash L, Zonder JA, Uberti JP, Abidi MH, Ratanatharathorn V.

Biol Blood Marrow Transplant. 2016 May;22(5):869-78. doi: 10.1016/j.bbmt.2015.12.030. Epub 2016 Jan 28.

14.

Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal.

Parajuli P, Anand R, Mandalaparty C, Suryadevara R, Sriranga PU, Michelhaugh SK, Cazacu S, Finniss S, Thakur A, Lum LG, Schalk D, Brodie C, Mittal S.

Oncotarget. 2016 Feb 2;7(5):6121-35. doi: 10.18632/oncotarget.6847.

15.

Activated T cells armed with bispecific antibodies kill tumor targets.

Bhutani D, Lum LG.

Curr Opin Hematol. 2015 Nov;22(6):476-83. doi: 10.1097/MOH.0000000000000176. Review.

PMID:
26457960
16.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):531-5. doi: 10.1016/j.clml.2015.05.008. Epub 2015 Jun 6.

PMID:
26166312
17.

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.

Vaishampayan U, Thakur A, Rathore R, Kouttab N, Lum LG.

Prostate Cancer. 2015;2015:285193. doi: 10.1155/2015/285193. Epub 2015 Feb 23.

18.

Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial.

Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, Dizon DS, Kouttab N, Maizel A, Colaiace W, Liu Q, Rathore R.

Clin Cancer Res. 2015 May 15;21(10):2305-14. doi: 10.1158/1078-0432.CCR-14-2280. Epub 2015 Feb 16.

19.

Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort.

Gul Z, Van Meter E, Abidi M, Ditah I, Abdul-Hussein M, Deol A, Ayash L, Lum LG, Waller EK, Ratanatharathorn V, Uberti J, Al-Kadhimi Z.

Bone Marrow Transplant. 2015 Mar;50(3):432-7. doi: 10.1038/bmt.2014.284. Epub 2015 Jan 19.

PMID:
25599169
20.

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.

Urbanska K, Lynn RC, Stashwick C, Thakur A, Lum LG, Powell DJ Jr.

J Transl Med. 2014 Dec 13;12:347. doi: 10.1186/s12967-014-0347-2.

21.

Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.

Bhutani D, Dyson G, Manasa R, Deol A, Ratanatharathorn V, Ayash L, Abidi M, Lum LG, Al-Kadhimi Z, Uberti JP.

Biol Blood Marrow Transplant. 2015 Jan;21(1):159-64. doi: 10.1016/j.bbmt.2014.10.004. Epub 2014 Oct 16.

22.

Hematopoietic cell transplantation and cellular therapeutics in the treatment of childhood malignancies.

Mallhi K, Lum LG, Schultz KR, Yankelevich M.

Pediatr Clin North Am. 2015 Feb;62(1):257-73. doi: 10.1016/j.pcl.2014.10.001. Review.

PMID:
25435122
23.

Maspin expression in prostate tumor elicits host anti-tumor immunity.

Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S.

Oncotarget. 2014 Nov 30;5(22):11225-36.

24.

Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.

Ratanatharathorn V, Deol A, Ayash L, Cronin S, Bhutani D, Lum LG, Abidi M, Ventimiglia M, Mellert K, Uberti JP.

Bone Marrow Transplant. 2015 Jan;50(1):106-12. doi: 10.1038/bmt.2014.203. Epub 2014 Oct 6.

25.

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells.

Yano H, Thakur A, Tomaszewski EN, Choi M, Deol A, Lum LG.

J Transl Med. 2014 Jul 9;12:191. doi: 10.1186/1479-5876-12-191.

26.

Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.

Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, Deol A.

J Clin Apher. 2014 Dec;29(6):293-8. doi: 10.1002/jca.21321. Epub 2014 Apr 3.

PMID:
24700728
27.

Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management.

Macedo FI, Faris J, Lum LG, Gabali A, Uberti JP, Ratanatharathorn V, White MT.

J Burn Care Res. 2014 Nov-Dec;35(6):e431-5. doi: 10.1097/BCR.0000000000000040.

PMID:
24476990
28.

Immunotherapy and immune evasion in prostate cancer.

Thakur A, Vaishampayan U, Lum LG.

Cancers (Basel). 2013 May 24;5(2):569-90. doi: 10.3390/cancers5020569.

29.

Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study.

Lum LG, Thakur A, Pray C, Kouttab N, Abedi M, Deol A, Colaiace WM, Rathore R.

Bone Marrow Transplant. 2014 Jan;49(1):73-9. doi: 10.1038/bmt.2013.133. Epub 2013 Sep 23.

30.

CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.

Lum LG, Thakur A, Liu Q, Deol A, Al-Kadhimi Z, Ayash L, Abidi MH, Pray C, Tomaszewski EN, Steele PA, Schalk DL, Yano H, Mitchell A, Dufresne M, Uberti JP, Ratanatharathorn V.

Biol Blood Marrow Transplant. 2013 Jun;19(6):925-33. doi: 10.1016/j.bbmt.2013.03.010. Epub 2013 Mar 22.

31.

Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.

Deol A, Abrams J, Masood A, Al-Kadhimi Z, Abidi MH, Ayash L, Lum LG, Ratanatharathorn V, Uberti JP.

Bone Marrow Transplant. 2013 Aug;48(8):1112-6. doi: 10.1038/bmt.2013.10. Epub 2013 Mar 11.

32.

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.

Zitron IM, Thakur A, Norkina O, Barger GR, Lum LG, Mittal S.

BMC Cancer. 2013 Feb 22;13:83. doi: 10.1186/1471-2407-13-83.

33.

Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway.

Thakur A, Schalk D, Tomaszewski E, Kondadasula SV, Yano H, Sarkar FH, Lum LG.

J Transl Med. 2013 Feb 9;11:35. doi: 10.1186/1479-5876-11-35.

34.

Pan-Bcl-2 inhibitor AT-101 enhances tumor cell killing by EGFR targeted T cells.

Thakur A, Lum LG, Schalk D, Azmi A, Banerjee S, Sarkar FH, Mohommad R.

PLoS One. 2012;7(11):e47520. doi: 10.1371/journal.pone.0047520. Epub 2012 Nov 19.

35.

Generation and immunologic functions of Th17 cells in malignant gliomas.

Paladugu M, Thakur A, Lum LG, Mittal S, Parajuli P.

Cancer Immunol Immunother. 2013 Jan;62(1):75-86. doi: 10.1007/s00262-012-1312-7. Epub 2012 Jul 1.

36.

Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.

Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1198-205. doi: 10.1002/pbc.24237. Epub 2012 Jun 15.

37.

Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.

Lum LG, Ramesh M, Thakur A, Mitra S, Deol A, Uberti JP, Pellett PE.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1012-22. doi: 10.1016/j.bbmt.2012.01.022. Epub 2012 Feb 5.

38.

The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.

Bao B, Thakur A, Li Y, Ahmad A, Azmi AS, Banerjee S, Kong D, Ali S, Lum LG, Sarkar FH.

Biochim Biophys Acta. 2012 Apr;1825(2):160-72. doi: 10.1016/j.bbcan.2011.11.002. Epub 2011 Nov 29. Review.

39.

Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity.

Dandawate S, Williams L, Joshee N, Rimando AM, Mittal S, Thakur A, Lum LG, Parajuli P.

Cancer Immunol Immunother. 2012 May;61(5):701-11. doi: 10.1007/s00262-011-1130-3. Epub 2011 Nov 6.

40.

Targeting T cells with bispecific antibodies for cancer therapy.

Lum LG, Thakur A.

BioDrugs. 2011 Dec 1;25(6):365-79. doi: 10.2165/11595950-000000000-00000. Review.

41.

A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells.

Thakur A, Schalk D, Sarkar SH, Al-Khadimi Z, Sarkar FH, Lum LG.

Cancer Immunol Immunother. 2012 Apr;61(4):497-509. doi: 10.1007/s00262-011-1116-1. Epub 2011 Oct 5.

42.
43.

In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.

Thakur A, Norkina O, Lum LG.

Cancer Immunol Immunother. 2011 Dec;60(12):1707-20. doi: 10.1007/s00262-011-1056-9. Epub 2011 Jun 29.

44.
45.

Large pericardial effusion as a complication in adults undergoing SCT.

Norkin M, Ratanatharathorn V, Ayash L, Abidi MH, Al-Kadhimi Z, Lum LG, Uberti JP.

Bone Marrow Transplant. 2011 Oct;46(10):1353-6. doi: 10.1038/bmt.2010.297. Epub 2010 Nov 29.

46.

Cancer therapy with bispecific antibodies: Clinical experience.

Thakur A, Lum LG.

Curr Opin Mol Ther. 2010 Jun;12(3):340-9. Review.

47.

Effect of disruption of Akt-1 of lin(-)c-kit(+) stem cells on myocardial performance in infarcted heart.

Tseng A, Stabila J, McGonnigal B, Yano N, Yang MJ, Tseng YT, Davol PA, Lum LG, Padbury JF, Zhao TC.

Cardiovasc Res. 2010 Sep 1;87(4):704-12. doi: 10.1093/cvr/cvq110. Epub 2010 Apr 21.

48.

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Deol A, Lum LG.

Cancer Treat Rev. 2010 Nov;36(7):528-38. doi: 10.1016/j.ctrv.2010.03.004. Epub 2010 Apr 9. Review.

49.

Triple MEL100 therapy in multiple myeloma.

Berz D, Colvin GA, McCormack EM, Winer ES, Karwan P, Colvin L, Rathore R, Lum LG, Elfenbein GJ, Quesenberry PJ.

Transplant Proc. 2009 Nov;41(9):3863-7. doi: 10.1016/j.transproceed.2009.06.196.

PMID:
19917402
50.

Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease.

Ibrahim RB, Abidi MH, Cronin SM, Lum LG, Al-Kadhimi Z, Ratanatharathorn V, Uberti JP.

Biol Blood Marrow Transplant. 2009 Apr;15(4):395-405. doi: 10.1016/j.bbmt.2008.12.487. Epub 2009 Feb 10. Review.

Supplemental Content

Support Center